112 cases of adverse drug reactions induced by azvudine tablets in patients with COVID-19
Objective To analyse the adverse drug reactions(ADR)induced by azvudine tablets in patients with COVID-19,to provide reference for rational drug use.Methods Clinical pharmacists provided pharmaceutical care for 352 patients with COVID-19 who received azfudine tablets in our hospital from November 1,2022 to January 15,2023.They inquired about the clinical manifestations of ADR,and recorded the general information,drug use,and liver and kidney function.Results The average age of patients who used azfudine tablets in our hospital was 74.60 years old,and patients over 60 years old accounted for 84.09%.Totally 112 ADR cases reported out of the 352 patients,with overall incidence 31.82%.The ADRs of azfudine tablets mainly included dizziness,headache,nausea,abdominal pain and elevated aminotransferase,among which the damage of the nervous system(26.16%),gastrointestinal system(25.00%)and hepatobiliary system(21.51%)accounted for a relatively high proportion.Univariate analysis indicated that the increase of transaminase was obviously correlated with the mean age and duration of medication.Conclusion Close monitoring of ADRs by azfudine tablets in patients with COVID-19 is needed.Elderly patients who take azfudine tablets for more than one week have a greater risk of elevated transaminase,so careful monitoring should be strengthened to ensure medication safety.
COVID-19azvudine tabletadverse drug reactionelevated transaminase
NETL
NSTL
万方数据
